SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum...
Day: November 10, 2021
Arbutus to Participate at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on...
Chalice Brands Ltd. to Report Third Quarter 2021 Financial and Operating Results
PORTLAND, Ore., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (“Chalice” or the “Company”), a...
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase...
LivaNova to Present at the 2021 Stifel and Jefferies Healthcare Conferences
LONDON--(BUSINESS WIRE)--#cardiovascular--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present...
Seven Healthcare Industry “High Reliability Organization Champions” Recognized by Patient Safety Movement Foundation
HRO Champion Designation Underscores Ongoing Commitment to Data Transparency and Becoming a Safe and Reliable Healthcare Organization IRVINE, Calif.--(BUSINESS WIRE)--#HROChampion--Medical...
Surescripts Announces Planned CEO Transition
Tom Skelton to Step Down in December 2022 After More Than Seven Years at Helm; Company Initiates Search for Successor...
Imbed Biosciences Wins a $2M Award From the U.S. Army to Prevent Combat Wound Infections
MADISON, Wis.--(BUSINESS WIRE)--#biofilm--Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded a contract for $1,999,481 by the U.S....
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
∙ Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected...
Better Plant Congratulates Affiliate NeonMind on Recent Achievements
VANCOUVER, BC / ACCESSWIRE / November 10, 2021 / Better Plant Sciences Inc. (CSE:PLNT)(OTCQB:VEGGF)(FRA:YG3) ("Better Plant" or the "Company"), a...
AlzeCure Publishes its Interim Report for January – September 2021
STOCKHOLM, SWEDEN / ACCESSWIRE / November 10, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today...
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTECHAMBURG, GERMANY...
IRLAB Publishes Interim Report for July 1 – September 30, 2021
GOTHENBURG, SWEDEN / ACCESSWIRE / November 10, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)IRLAB today published its interim report for the...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2022 Financial Results on November 16, 2021
Financials for Second Quarter Fiscal Year 2022 Ended September 30, 2021 will be released November 15, 2021NORTHVALE, NJ / ACCESSWIRE...